GlassScriptPhysician profile
Sajjad Habib
NPI 1528019619
$4,193.88
in general payments reported to CMS, 2019-2025
25 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $468 · 2021: $929 · 2022: $898 · 2023: $459 · 2024: $448 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $47.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.58 |
| Education | $47.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.13 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $618.41 | 2021-2024 | |
| Akebia Therapeutics INC | $609.25 | 2019-2024 | Vafseo, Auryxia |
| Janssen Biotech, INC. | $243.56 | 2025 | Tremfya |
| Amgen INC. | $236.47 | 2019-2024 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $202.98 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $192.44 | 2019-2024 | Velphoro |
| Mallinckrodt Enterprises LLC | $164.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $153.79 | 2021-2022 | |
| Genzyme Corporation | $144.99 | 2021 | |
| Opko Pharmaceuticals, LLC | $123.42 | 2019-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $94.59 | 2021-2024 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $92.25 | 2019-2024 | Jynarque |
| Daiichi Sankyo INC. | $60.23 | 2020-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $49.57 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $39.94 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $37.90 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.77 | 2023-2024 | Jardiance |
| Travere Therapeutics, INC. | $31.89 | 2023 | |
| Lilly USA, LLC | $26.77 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $23.06 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $16.79 | 2024 | |
| Ardelyx, INC. | $16.26 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $15.91 | 2024 | Benlysta |
| Calliditas Therapeutics US INC. | $15.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Habib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.